Skip to main content

Peer Review reports

From: Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

Original Submission
21 Dec 2021 Submitted Original manuscript
9 Mar 2022 Reviewed Reviewer Report
27 Mar 2022 Reviewed Reviewer Report - HAKAN AKIN
4 Apr 2022 Reviewed Reviewer Report
20 Apr 2022 Author responded Author comments - Laurent Peyrin-Biroulet
Resubmission - Version 2
20 Apr 2022 Submitted Manuscript version 2
28 Apr 2022 Reviewed Reviewer Report
2 May 2022 Reviewed Reviewer Report
19 May 2022 Author responded Author comments - Laurent Peyrin-Biroulet
Resubmission - Version 3
19 May 2022 Submitted Manuscript version 3
Publishing
24 May 2022 Editorially accepted
8 Jun 2022 Article published 10.1186/s12876-022-02347-1

You can find further information about peer review here.

Back to article page